{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:23:25Z","timestamp":1790270605145,"version":"4.1.0"},"reference-count":60,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (Fc\u03b5RI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in Fc\u03b5RI baseline levels and subsequent median increase in Urticaria Control Test was evidenced after omalizumab prescription in all patients. Drug survival at 48 months was at 88.9%. Omalizumab stepping-down protocol led to sustained omalizumab discontinuation in only 1 patient. Median basal Urticaria Control Test was lower (p\u2009&lt;\u20090.01) in patients who were prescribed omalizumab and in patients without remission. This study contributes to our knowledge of omalizumab outcomes in real-life clinical practice and highlights the pathogenic importance of IgE-mediated pathways in solar urticaria, where Fc\u03b5RI emerges as a possible biomarker of omalizumab response.<\/jats:p>","DOI":"10.2340\/actadv.v104.25576","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:04:23Z","timestamp":1704686663000},"page":"adv25576","source":"Crossref","is-referenced-by-count":14,"title":["Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes"],"prefix":"10.2340","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-9780","authenticated-orcid":false,"given":"David","family":"Pesqu\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ciudad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Andrades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon M.","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-7753","authenticated-orcid":false,"given":"Ana M.","family":"Gim\u00e9nez-Arnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"45280","doi-asserted-by":"crossref","unstructured":"Goetze S, Elsner P. Solar urticaria. J Dtsch Dermatol Ges 2015; 13: 1250-1253.","DOI":"10.1111\/ddg.12809"},{"key":"45281","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.12809","DOI":"10.1111\/ddg.12809"},{"key":"45282","doi-asserted-by":"crossref","unstructured":"McSweeney SM, Sarkany R, Fassihi H, Tziotzios C, McGrath JA. Pathogenesis of solar urticaria: Classic perspectives and emerging concepts. Exp Dermatol 2022; 31: 586-593.","DOI":"10.1111\/exd.14493"},{"key":"45283","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.14493","DOI":"10.1111\/exd.14493"},{"key":"45284","doi-asserted-by":"crossref","unstructured":"McSweeney SM, Kloczko E, Chadha M, Sarkany R, Fassihi H, Tziotzios C, et al. Systematic review of the clinical characteristics and natural history of solar urticaria. J Am Acad Dermatol 2023; 89: 138-140.","DOI":"10.1016\/j.jaad.2023.01.039"},{"key":"45285","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2023.01.039","DOI":"10.1016\/j.jaad.2023.01.039"},{"key":"45286","doi-asserted-by":"crossref","unstructured":"Haylett AK, Koumaki D, Rhodes LE. Solar urticaria in 145 patients: assessment of action spectra and impact on quality of life in adults and children. Photodermatol Photoimmunol Photomed 2018; 34: 262-268.","DOI":"10.1111\/phpp.12385"},{"key":"45287","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/phpp.12385","DOI":"10.1111\/phpp.12385"},{"key":"45288","doi-asserted-by":"crossref","unstructured":"Yu M, Terhorst-Molawi D, Altrichter S, Hawro T, Chen YD, Liu B, et al. Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response. Clin Exp Allergy 2021; 51: 730-734.","DOI":"10.1111\/cea.13838"},{"key":"45289","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/cea.13838","DOI":"10.1111\/cea.13838"},{"key":"45290","doi-asserted-by":"crossref","unstructured":"Maurer M, Raap U, Staubach P, Richter-Huhn G, Bauer A, Oppel EM, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019; 49: 655-662.","DOI":"10.1111\/cea.13309"},{"key":"45291","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/cea.13309","DOI":"10.1111\/cea.13309"},{"key":"45292","doi-asserted-by":"crossref","unstructured":"Maurer M, Church MK, Gon\u00e7alo M, Sussman G, S\u00e1nchez-Borges M. Management and treatment of chronic urticaria (CU). J Eur Acad Dermatol Venereol 2015; 29: 16-32.","DOI":"10.1111\/jdv.13198"},{"key":"45293","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.13198","DOI":"10.1111\/jdv.13198"},{"key":"45294","doi-asserted-by":"crossref","unstructured":"Aubin F, Avenel-Audran M, Jeanmougin M, Adamski H, Peyron JL, Marguery MC, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study. J Am Acad Dermatol 2016; 74: 574-575.","DOI":"10.1016\/j.jaad.2015.11.021"},{"key":"45295","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2015.11.021","DOI":"10.1016\/j.jaad.2015.11.021"},{"key":"45296","doi-asserted-by":"crossref","unstructured":"Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol 2018; 141: 638-649.","DOI":"10.1016\/j.jaci.2017.06.032"},{"key":"45297","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2017.06.032","DOI":"10.1016\/j.jaci.2017.06.032"},{"key":"45298","doi-asserted-by":"crossref","unstructured":"Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, et al. Omalizumab for the treatment of solar urticaria: case series and systematic review of the literature. J Allergy Clin Immunol Pract 2018; 6: 1198-1204.e3.","DOI":"10.1016\/j.jaip.2018.02.032"},{"key":"45299","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2018.02.032","DOI":"10.1016\/j.jaip.2018.02.032"},{"key":"45300","doi-asserted-by":"crossref","unstructured":"Navarro-Trivi\u00f1o FJ, Prados-Carmona A, Aguilera J, de G\u00e1lvez MV, Ruiz-Villaverde R. Treatment of refractory solar urticaria: could dupilumab fill the current gap? J Dtsch Dermatol Ges 2023; 21: 652-653.","DOI":"10.1111\/ddg.15025"},{"key":"45301","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.15025","DOI":"10.1111\/ddg.15025"},{"key":"45302","doi-asserted-by":"crossref","unstructured":"Deza G, Bertol\u00edn-Colilla M, Pujol RM, Curto-Barredo L, Soto D, Garc\u00eda M, et al. Basophil Fc\u03b5RI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol 2017; 97: 698-704.","DOI":"10.2340\/00015555-2654"},{"key":"45303","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2654","DOI":"10.2340\/00015555-2654"},{"key":"45304","doi-asserted-by":"crossref","unstructured":"Mo\u00f1ino-Romero S, Kolkhir P, Ohanyan T, Sz\u00e9pfalusi Z, Weller K, Metz M, et al. Elevated baseline soluble Fc\u03b5RI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2024; 38: 167-174.","DOI":"10.1111\/jdv.19485"},{"key":"45305","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19485","DOI":"10.1111\/jdv.19485"},{"key":"45306","doi-asserted-by":"crossref","unstructured":"Spertino J, Curto-Barredo L, Rozas-Mu\u00f1oz E, Figueras-Nart I, Gimenez-Arnau A, Serra-Baldrich E, et al. Algorithm for treatment of chronic spontaneous urticaria with omalizumab. Actas Dermosifiliogr (Engl Ed) 2018; 109: 771-776.","DOI":"10.1016\/j.adengl.2018.09.011"},{"key":"45307","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ad.2018.07.005","DOI":"10.1016\/j.ad.2018.07.005"},{"key":"45308","doi-asserted-by":"crossref","unstructured":"De Argila D, Aguilera J, S\u00e1nchez J, Garc\u00eda-D\u00edez A. Study of idiopathic, exogenous photodermatoses, part II: photobiologic testing. Actas Dermosifiliogr 2014; 105: 233-242.","DOI":"10.1016\/j.adengl.2012.07.040"},{"key":"45309","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ad.2012.07.024","DOI":"10.1016\/j.ad.2012.07.024"},{"key":"45310","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Ferriols A, Aguilera J, Aguilera P, de Argila D, Barnadas MA, de Cabo X, et al. Determination of minimal erythema dose and anomalous reactions to UVA radiation by skin phototype. Actas Dermosifiliogr 2014; 105: 780-788.","DOI":"10.1016\/j.adengl.2014.05.020"},{"key":"45311","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.adengl.2014.05.020","DOI":"10.1016\/j.adengl.2014.05.020"},{"key":"45312","doi-asserted-by":"crossref","unstructured":"Magerl M, Altrichter S, Borzova E, Gim\u00e9nez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - the EAACI\/GA(2) LEN\/EDF\/UNEV consensus recommendations 2016 update and revision. Allergy 2016; 71: 780-802.","DOI":"10.1111\/all.12884"},{"key":"45313","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.12884","DOI":"10.1111\/all.12884"},{"key":"45314","doi-asserted-by":"crossref","unstructured":"Morgado-Carrasco D, Fust\u00e0-Novell X, Podlipnik S, Combalia A, Aguilera P. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature. Photodermatol Photoimmunol Photomed 2018; 34: 194-199.","DOI":"10.1111\/phpp.12370"},{"key":"45315","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/phpp.12370","DOI":"10.1111\/phpp.12370"},{"key":"45316","doi-asserted-by":"crossref","unstructured":"Snast I, Lapidoth M, Uvaidov V, Enk CD, Mazor S, Hodak E, et al. Real-life experience in the treatment of solar urticaria: retrospective cohort study. Clin Exp Dermatol 2019; 44: e164-e170.","DOI":"10.1111\/ced.13960"},{"key":"45317","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.13960","DOI":"10.1111\/ced.13960"},{"key":"45318","doi-asserted-by":"crossref","unstructured":"Photiou L, Foley P, Ross G. Solar urticaria - an Australian case series of 83 patients. Australas J Dermatol 2019; 60: 110-117.","DOI":"10.1111\/ajd.12975"},{"key":"45319","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ajd.12975","DOI":"10.1111\/ajd.12975"},{"key":"45320","doi-asserted-by":"crossref","unstructured":"Kishimoto I, Uetsu N, Tanimura H, Fujii H, Okamoto H. Solar urticaria with a wide action spectrum from UVB to visible light complicated with UVA-induced polymorphous light eruption. Photodermatol Photoimmunol Photomed 2017; 33: 172-175.","DOI":"10.1111\/phpp.12300"},{"key":"45321","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/phpp.12300","DOI":"10.1111\/phpp.12300"},{"key":"45322","doi-asserted-by":"crossref","unstructured":"Pesqu\u00e9 D, March-Rodr\u00edguez \u00c1, Curto-Barredo L, Soto D, Gimeno R, Pujol RM, et al. Autoimmune diseases and low baseline immunoglobulin E in chronic spontaneous urticaria: a clinical and therapeutic prospective analysis in real clinical practice. J Allergy Clin Immunol Pract 2023; 11: 3763-3771.e5","DOI":"10.1016\/j.jaip.2023.09.002"},{"key":"45323","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2023.09.002","DOI":"10.1016\/j.jaip.2023.09.002"},{"key":"45324","doi-asserted-by":"crossref","unstructured":"Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and Fc\u03b5RI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.","DOI":"10.1016\/j.jaci.2003.11.044"},{"key":"45325","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2003.11.044","DOI":"10.1016\/j.jaci.2003.11.044"},{"key":"45326","doi-asserted-by":"crossref","unstructured":"Oliver JM, Tarleton CA, Gilmartin L, Archibeque T, Qualls CR, Diehl L, et al. Reduced Fc\u03b5RI-mediated release of asthma- promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010; 151: 275-284.","DOI":"10.1159\/000250436"},{"key":"45327","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000250436","DOI":"10.1159\/000250436"},{"key":"45328","doi-asserted-by":"crossref","unstructured":"Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C. Structural and physical basis for anti-IgE therapy. Sci Rep 2015; 5: 11581.","DOI":"10.1038\/srep11581"},{"key":"45329","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/srep11581","DOI":"10.1038\/srep11581"},{"key":"45330","doi-asserted-by":"crossref","unstructured":"Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell Fc\u03b5RI expression. J Allergy Clin Immunol 2003; 112: 1147-1154","DOI":"10.1016\/j.jaci.2003.10.003"},{"key":"45331","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2003.10.003","DOI":"10.1016\/j.jaci.2003.10.003"},{"key":"45332","doi-asserted-by":"crossref","unstructured":"Kocat\u00fcrk E, Can PK, Akbas PE, Copur M, Degirmentepe EN, K\u0131z\u0131ltac K, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study. J Dermatol Sci 2017; 87: 60-69.","DOI":"10.1016\/j.jdermsci.2017.02.283"},{"key":"45333","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2017.02.283","DOI":"10.1016\/j.jdermsci.2017.02.283"},{"key":"45334","doi-asserted-by":"crossref","unstructured":"Morgado-Carrasco D, Gi\u00e1caman-Von der Weth M, Fust\u00e1-Novell X, Podlipnik S, P\u00e9rez-Ferriols A, Aguilera P. Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab. J Am Acad Dermatol 2023; 88: 1110-1111.","DOI":"10.1016\/j.jaad.2019.05.070"},{"key":"45335","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.070","DOI":"10.1016\/j.jaad.2019.05.070"},{"key":"45336","doi-asserted-by":"crossref","unstructured":"Vollono L, Bianchi L, Piccolo A, Mazzilli S, Campione E, Diluvio L Good things come to those who wait: Successful response of solar urticaria to omalizumab after 1 year of treatment. Photodermatol Photoimmunol Photomed 2020; 36: 408-411.","DOI":"10.1111\/phpp.12577"},{"key":"45337","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/phpp.12577","DOI":"10.1111\/phpp.12577"},{"key":"45338","doi-asserted-by":"crossref","unstructured":"Spekhorst LS, van den Reek JMPA, Knulst AC, R\u00f6ckmann H. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria. Allergy 2019; 74: 1185-1187.","DOI":"10.1111\/all.13714"},{"key":"45339","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.13714","DOI":"10.1111\/all.13714"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/25576\/42389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/25576\/42389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:05:24Z","timestamp":1704686724000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/25576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":60,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.25576","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}